{
    "hands_on_practices": [
        {
            "introduction": "To understand the public health threat posed by multidrug-resistant (MDR) *Acinetobacter*, we must first be able to quantify its clinical impact. This practice uses the principles of clinical epidemiology to analyze hypothetical patient cohort data, a common task in infectious disease surveillance. By calculating the crude risk ratio and reasoning about the influence of confounding variables like the severity of illness, you will gain hands-on experience in interpreting the data that informs hospital infection control policies and treatment guidelines .",
            "id": "4654923",
            "problem": "A tertiary-care hospital conducts a prospective cohort study of bloodstream infections due to Acinetobacter species to estimate how multidrug resistance influences short-term mortality. Multidrug-resistant (MDR) status is defined using standard susceptibility testing across multiple antibiotic classes. Severity of illness at bacteremia onset is measured by the Acute Physiology and Chronic Health Evaluation II (APACHE II) score and is categorized as high severity if the score is at least $20$.\n\nOver the study period, the following data are recorded for patients with monomicrobial Acinetobacter bacteremia:\n\n- MDR group: total $N_{MDR} = 150$ patients, consisting of $90$ with high severity (of whom $45$ die within $30$ days) and $60$ with low severity (of whom $12$ die within $30$ days).\n- Susceptible group: total $N_{SUS} = 200$ patients, consisting of $60$ with high severity (of whom $18$ die within $30$ days) and $140$ with low severity (of whom $14$ die within $30$ days).\n\nAssume no loss to follow-up within $30$ days and that death status is ascertained for all patients. Using first principles of cohort risk and causal inference, compute the crude risk ratio of $30$-day mortality comparing MDR to susceptible Acinetobacter bacteremia. Then, using the severity-of-illness strata provided, reason about how severity of illness could act as a confounder of the crude association.\n\nReport only the crude risk ratio as your final numeric answer. Express the risk ratio as a decimal, and round your answer to four significant figures.",
            "solution": "The problem statement is evaluated and deemed valid. It is scientifically grounded in the principles of clinical epidemiology, self-contained with all necessary data for the requested calculations and reasoning, and well-posed. The data provided are internally consistent: for the multidrug-resistant (MDR) group, the sum of patients in the high-severity ($90$) and low-severity ($60$) strata equals the total ($150$); for the susceptible group, the sum of patients in the high-severity ($60$) and low-severity ($140$) strata equals the total ($200$). The task is objective and requires the application of standard epidemiological methods.\n\nThe primary task is to compute the crude risk ratio of $30$-day mortality, comparing patients with MDR *Acinetobacter* bacteremia to those with susceptible strains. A risk ratio ($RR$) is a measure of association between an exposure and an outcome, defined as the ratio of the risk of the outcome in the exposed group to the risk of the outcome in the unexposed group.\n\nLet $R_{MDR}$ denote the risk of $30$-day mortality in the MDR group (the exposed group).\nLet $R_{SUS}$ denote the risk of $30$-day mortality in the susceptible group (the unexposed group).\n\nThe risk in each group is calculated as the number of individuals who experience the outcome (death) divided by the total number of individuals in that group.\n\nFirst, we calculate the total number of deaths ($D_{MDR}$) and the total number of patients ($N_{MDR}$) in the MDR group. The data are provided stratified by severity.\nTotal patients in MDR group: $N_{MDR} = 150$.\nDeaths in the high-severity MDR subgroup: $45$.\nDeaths in the low-severity MDR subgroup: $12$.\nTotal deaths in the MDR group:\n$$D_{MDR} = 45 + 12 = 57$$\nThe risk of mortality in the MDR group is therefore:\n$$R_{MDR} = \\frac{D_{MDR}}{N_{MDR}} = \\frac{57}{150}$$\n\nNext, we calculate the total number of deaths ($D_{SUS}$) and the total number of patients ($N_{SUS}$) in the susceptible group.\nTotal patients in susceptible group: $N_{SUS} = 200$.\nDeaths in the high-severity susceptible subgroup: $18$.\nDeaths in the low-severity susceptible subgroup: $14$.\nTotal deaths in the susceptible group:\n$$D_{SUS} = 18 + 14 = 32$$\nThe risk of mortality in the susceptible group is therefore:\n$$R_{SUS} = \\frac{D_{SUS}}{N_{SUS}} = \\frac{32}{200}$$\n\nThe crude risk ratio ($RR_{crude}$) is the ratio of these two risks:\n$$RR_{crude} = \\frac{R_{MDR}}{R_{SUS}} = \\frac{57/150}{32/200}$$\nWe perform the numerical calculation:\n$$R_{MDR} = \\frac{57}{150} = 0.38$$\n$$R_{SUS} = \\frac{32}{200} = 0.16$$\n$$RR_{crude} = \\frac{0.38}{0.16} = 2.375$$\nRounding to four significant figures, the crude risk ratio is $2.375$. This suggests that patients with MDR bacteremia have $2.375$ times the risk of dying within $30$ days compared to patients with susceptible bacteremia.\n\nThe second part of the task is to reason about how severity of illness could act as a confounder. A variable is a confounder if it meets three criteria:\n$1$. It is associated with the outcome (mortality).\n$2$. It is associated with the exposure (MDR status).\n$3$. It is not on the causal pathway from the exposure to the outcome.\n\nLet's examine each criterion for \"severity of illness\":\n\nCriterion $1$: Association with the outcome (mortality).\nWe assess if high severity is a risk factor for death, independent of MDR status.\nLet's calculate the overall risk of death in the high-severity stratum versus the low-severity stratum.\nTotal patients with high severity: $90$ (MDR) $+ 60$ (SUS) $= 150$.\nTotal deaths in high-severity patients: $45$ (MDR) $+ 18$ (SUS) $= 63$.\nRisk in high-severity stratum: $R_{high} = \\frac{63}{150} = 0.42$.\nTotal patients with low severity: $60$ (MDR) $+ 140$ (SUS) $= 200$.\nTotal deaths in low-severity patients: $12$ (MDR) $+ 14$ (SUS) $= 26$.\nRisk in low-severity stratum: $R_{low} = \\frac{26}{200} = 0.13$.\nSince the risk of death is substantially higher in the high-severity group ($0.42$) compared to the low-severity group ($0.13$), severity of illness is strongly associated with the outcome.\n\nCriterion $2$: Association with the exposure (MDR status).\nWe check if the distribution of the severity of illness is different between the MDR and susceptible groups.\nProportion of high-severity patients in the MDR group: $\\frac{90}{150} = 0.60$ or $60\\%$.\nProportion of high-severity patients in the susceptible group: $\\frac{60}{200} = 0.30$ or $30\\%$.\nSince these proportions are different, with the MDR group having a higher prevalence of severely ill patients, severity of illness is associated with the exposure.\n\nCriterion $3$: Not on the causal pathway.\nThe problem states that severity is measured by the APACHE II score at bacteremia onset. The MDR status of the infecting organism does not cause the patient's acute physiological derangement present at the time of diagnosis. Rather, it is more plausible that sicker patients (e.g., those with longer hospital stays, more prior antibiotic exposure) are more likely to acquire an MDR organism. Therefore, severity of illness is not on the causal pathway from MDR status to mortality.\n\nSince all three criteria are met, severity of illness is a confounder in the relationship between MDR status and mortality. The crude risk ratio of $2.375$ is a biased estimate of the true effect of MDR on mortality. Because the confounding variable (high severity) is a risk factor for the outcome and is more prevalent in the exposed (MDR) group, it results in positive confounding, meaning the crude RR overestimates the true causal effect.\n\nTo illustrate this, we can calculate the stratum-specific risk ratios:\nFor the high-severity stratum:\n$R_{MDR, high} = \\frac{45}{90} = 0.5$\n$R_{SUS, high} = \\frac{18}{60} = 0.3$\n$RR_{high} = \\frac{0.5}{0.3} \\approx 1.667$\nFor the low-severity stratum:\n$R_{MDR, low} = \\frac{12}{60} = 0.2$\n$R_{SUS, low} = \\frac{14}{140} = 0.1$\n$RR_{low} = \\frac{0.2}{0.1} = 2.0$\n\nBoth stratum-specific RRs ($1.667$ and $2.0$) are lower than the crude RR ($2.375$), which confirms the presence of positive confounding. The crude association is distorted upwards because a larger fraction of the MDR group was already at high risk of death due to their severe underlying illness. The final reported answer is the value of the crude risk ratio as requested.",
            "answer": "$$\\boxed{2.375}$$"
        },
        {
            "introduction": "Understanding the clinical impact of MDR *Acinetobacter* leads to a crucial question: how does it become resistant at a molecular level? This problem challenges you to act as a microbial geneticist, applying your knowledge of the central dogma and membrane biochemistry to compare two distinct resistance mechanisms. By predicting the phenotypic outcomes of enzymatic inactivation versus efflux pump overexpression and devising experiments to tell them apart, you will develop the critical thinking skills needed to characterize novel resistance threats .",
            "id": "4654970",
            "problem": "An Acinetobacter baumannii clinical isolate is initially susceptible to tigecycline with a minimum inhibitory concentration (MIC) of $0.5\\,\\mu\\mathrm{g}\\,\\mathrm{mL}^{-1}$. Two derivative isolates arise independently from this parent: one acquires the gene tetX, and the other overexpresses the Resistance-Nodulation-Division (RND) efflux pump AdeABC due to a mutation in its AdeRS two-component regulator. You are asked to apply fundamental principles to predict how tigecycline susceptibility will change in each derivative and to choose an experimental strategy that can distinguish the resistance mechanisms.\n\nUse the following foundational bases:\n- Central Dogma of Molecular Biology: genes encode proteins that perform biochemical functions; increased gene expression increases the amount of the corresponding protein.\n- Enzyme kinetics and antibiotic inactivation: a drug-inactivating enzyme reduces the concentration of active antibiotic in its environment by catalyzing a chemical modification of the antibiotic substrate.\n- Membrane transport and efflux: an RND efflux pump uses the proton motive force to drive active export of structurally diverse substrates, lowering intracellular drug concentration; inhibition of the pump increases intracellular drug accumulation.\n- Antibiotic mechanism of action: tigecycline is a glycylcycline that binds the $30\\mathrm{S}$ ribosomal subunit to inhibit protein synthesis.\n\nWhich option best predicts the phenotypic changes in tigecycline susceptibility when the isolate acquires tetX versus overexpresses AdeABC and proposes an experiment that would distinguish these mechanisms on first principles?\n\nA. Acquisition of tetX produces high-level, class-wide resistance across tigecycline, minocycline, and eravacycline with no reversal by an efflux pump inhibitor such as phenyl-arginine-beta-naphthylamide (PAβN); spent, cell-free culture supernatants from the tetX isolate inactivate tigecycline in a cell-free assay as confirmed by liquid chromatography–mass spectrometry (LC–MS) or a bioassay. Overexpression of AdeABC produces a moderate increase in tigecycline MIC that is reversed by PAβN and is accompanied by reduced intracellular accumulation of a fluorescent substrate (for example, ethidium bromide), with no tigecycline inactivation in supernatants.\n\nB. Acquisition of tetX increases only tigecycline MIC, not other tetracyclines, and this increase is reversed by PAβN; supernatants from the tetX isolate do not alter tigecycline activity. Overexpression of AdeABC increases MICs for all tetracyclines with no reversal by PAβN, and supernatants from the AdeABC isolate inactivate tigecycline, confirming efflux-mediated resistance.\n\nC. Both tetX and AdeABC overexpression cause identical high-level tigecycline resistance that cannot be modulated by efflux inhibitors; the only definitive way to distinguish them is whole-genome sequencing because no phenotypic assays are informative.\n\nD. Acquisition of tetX primarily reduces susceptibility to carbapenems, while AdeABC overexpression specifically affects beta-lactams; to distinguish them, test for synergy between tigecycline and clavulanate using a checkerboard assay and interpret a fractional inhibitory concentration index of $\\leq 0.5$ as evidence for enzymatic inactivation.",
            "solution": "The problem statement is evaluated for validity prior to attempting a solution.\n\n**Step 1: Extract Givens**\n- **Organism**: An *Acinetobacter baumannii* clinical isolate.\n- **Initial State**: Susceptible to tigecycline with a Minimum Inhibitory Concentration (MIC) of $0.5\\,\\mu\\mathrm{g}/\\mathrm{mL}$.\n- **Derivative Isolate 1**: Acquires the gene `tetX`.\n- **Derivative Isolate 2**: Overexpresses the Resistance-Nodulation-Division (RND) efflux pump `AdeABC` due to a mutation in its `AdeRS` two-component regulator.\n- **Question**: Predict the change in tigecycline susceptibility for each derivative and choose an experimental strategy to distinguish the mechanisms.\n- **Foundational Principles**:\n    1.  Central Dogma: Genes encode proteins; increased gene expression leads to increased protein abundance.\n    2.  Enzyme Kinetics: A drug-inactivating enzyme catalyzes a chemical modification of an antibiotic, reducing its active concentration.\n    3.  Membrane Transport: An RND efflux pump uses proton motive force for active drug export, lowering intracellular drug concentration. Pump inhibition reverses this effect.\n    4.  Antibiotic Action: Tigecycline inhibits protein synthesis by binding to the $30\\mathrm{S}$ ribosomal subunit.\n\n**Step 2: Validate Using Extracted Givens**\n- **Scientific Grounding**: The problem is scientifically grounded. `tetX` is a known gene encoding a flavin-dependent monooxygenase that inactivates tigecycline. `AdeABC` is a well-characterized RND efflux pump in *A. baumannii* whose overexpression, often due to mutations in the `AdeRS` regulatory system, confers resistance to tigecycline and other antibiotics. The given principles are fundamental and correct tenets of molecular biology and microbiology. The initial MIC value is realistic for a susceptible isolate.\n- **Well-Posedness**: The problem is well-posed. It presents two distinct, well-defined genetic changes and asks for their predictable phenotypic consequences based on a provided set of principles. The question is unambiguous and seeks a single best answer that combines prediction with experimental differentiation.\n- **Objectivity**: The problem is stated in objective, scientific language, free from subjectivity or ambiguity.\n\n**Step 3: Verdict and Action**\nThe problem statement is **valid**. It is scientifically sound, well-posed, and objective. It provides a clear basis for deriving a solution from first principles. I will now proceed with the solution.\n\n**Derivation of Solution**\n\nThe objective is to predict the phenotypic consequences of two distinct resistance mechanisms and identify an experimental strategy to differentiate them based on the provided foundational principles.\n\n**Analysis of Derivative 1: Acquisition of `tetX`**\n1.  **Mechanism**: According to the Central Dogma, the acquired `tetX` gene will be expressed to produce the TetX protein. The principle of enzyme kinetics states that a drug-inactivating enzyme reduces the active concentration of the drug. The TetX protein is such an enzyme, specifically a monooxygenase that chemically modifies and destroys tigecycline.\n2.  **Phenotypic Prediction**:\n    - **Resistance Level**: Enzymatic inactivation is a highly effective resistance mechanism as it directly eliminates the drug. This is expected to cause a significant, *high-level* increase in the tigecycline MIC, often rendering the drug clinically useless.\n    - **Resistance Spectrum**: The `tetX` enzyme modifies the core tetracycline structure. Therefore, its activity is likely not limited to tigecycline but will extend to other advanced tetracyclines like minocycline and eravacycline, resulting in *class-wide resistance*.\n    - **Effect of Efflux Pump Inhibitors (EPIs)**: The mechanism is enzymatic destruction, not active efflux. Therefore, an inhibitor of RND efflux pumps, such as phenyl-arginine-$\\beta$-naphthylamide (PA$\\beta$N), will have **no effect** on the activity of the TetX enzyme. The MIC should remain high in the presence of PA$\\beta$N.\n    - **Experimental Signature**: The definitive test for enzymatic inactivation is to demonstrate the loss of active drug. A cell-free supernatant from a culture of the `tetX`-positive isolate should contain the inactivated tigecycline metabolite. This can be directly confirmed by analytical chemistry, such as liquid chromatography–mass spectrometry (LC–MS), which would detect the parent tigecycline molecule disappearing and a new peak corresponding to the modified, higher-mass product appearing. Alternatively, a bioassay could be used: the spent supernatant would fail to inhibit the growth of the original susceptible parent strain, proving the antibacterial activity has been destroyed.\n\n**Analysis of Derivative 2: Overexpression of `AdeABC`**\n1.  **Mechanism**: A mutation in the `AdeRS` regulator leads to constitutive high-level expression of the `adeABC` genes (Central Dogma). This results in an abundance of the AdeABC RND efflux pump in the cell membrane. The principle of membrane transport states this pump will use energy (proton motive force) to actively export substrates, including tigecycline, from the cell.\n2.  **Phenotypic Prediction**:\n    - **Resistance Level**: Efflux works by lowering the intracellular drug concentration below the inhibitory threshold at the target (the ribosome). It is a continuous competition between drug influx and efflux. This typically results in a *low-to-moderate* increase in MIC, as compared to the more absolute effect of enzymatic destruction.\n    - **Effect of Efflux Pump Inhibitors (EPIs)**: The resistance is directly dependent on the function of the AdeABC pump. An EPI like PA$\\beta$N competes for the pump or disrupts its energy source, thereby inhibiting its function. Consequently, tigecycline is no longer efficiently exported, its intracellular concentration increases, and susceptibility is restored. This is observed as a significant *reduction in MIC* in the presence of the EPI.\n    - **Experimental Signature**: The overexpression of a functional efflux pump can be demonstrated by measuring its activity on other substrates. RND pumps are often polyspecific and can export fluorescent dyes. A cell with an overexpressed AdeABC pump will exhibit *reduced intracellular accumulation* of a fluorescent substrate like ethidium bromide or acriflavine compared to the parent strain. This is measurable via fluorometry. Furthermore, since the pump only exports the drug without modifying it, the tigecycline in the culture supernatant remains chemically intact and active. A cell-free supernatant assay would show *no inactivation* of the drug.\n\n**Evaluation of Options**\n\n**A. Acquisition of tetX produces high-level, class-wide resistance across tigecycline, minocycline, and eravacycline with no reversal by an efflux pump inhibitor such as phenyl-arginine-beta-naphthylamide (PAβN); spent, cell-free culture supernatants from the tetX isolate inactivate tigecycline in a cell-free assay as confirmed by liquid chromatography–mass spectrometry (LC–MS) or a bioassay. Overexpression of AdeABC produces a moderate increase in tigecycline MIC that is reversed by PAβN and is accompanied by reduced intracellular accumulation of a fluorescent substrate (for example, ethidium bromide), with no tigecycline inactivation in supernatants.**\n- This option accurately describes the predicted phenotypes for both mechanisms based on our derivation. It correctly predicts high-level, non-EPI-reversible resistance for `tetX` and moderate-level, EPI-reversible resistance for `AdeABC` overexpression. It also proposes the correct and definitive experimental assays to distinguish them: supernatant inactivation for `tetX` and EPI synergy/fluorescent substrate accumulation for `AdeABC`.\n- **Verdict: Correct.**\n\n**B. Acquisition of tetX increases only tigecycline MIC, not other tetracyclines, and this increase is reversed by PAβN; supernatants from the tetX isolate do not alter tigecycline activity. Overexpression of AdeABC increases MICs for all tetracyclines with no reversal by PAβN, and supernatants from the AdeABC isolate inactivate tigecycline, confirming efflux-mediated resistance.**\n- This option incorrectly describes both mechanisms. For `tetX`, it wrongly claims narrow-spectrum activity, reversal by an EPI, and no drug inactivation. For `AdeABC`, it incorrectly states that resistance is not reversible by an EPI and that supernatants inactivate the drug. It fundamentally confuses the characteristics of enzymatic inactivation and efflux.\n- **Verdict: Incorrect.**\n\n**C. Both tetX and AdeABC overexpression cause identical high-level tigecycline resistance that cannot be modulated by efflux inhibitors; the only definitive way to distinguish them is whole-genome sequencing because no phenotypic assays are informative.**\n- This option is flawed. It falsely claims the resistance levels are identical and that `AdeABC`-mediated resistance is not reversible by EPIs. Most critically, it denies the utility of phenotypic assays, which, as demonstrated in the derivation and in option A, are highly informative and are the standard methods for functional characterization of resistance mechanisms. While whole-genome sequencing can identify the genes, it does not confirm their functional expression without complementary phenotypic data.\n- **Verdict: Incorrect.**\n\n**D. Acquisition of tetX primarily reduces susceptibility to carbapenems, while AdeABC overexpression specifically affects beta-lactams; to distinguish them, test for synergy between tigecycline and clavulanate using a checkerboard assay and interpret a fractional inhibitory concentration index of $\\leq 0.5$ as evidence for enzymatic inactivation.**\n- This option is factually wrong regarding the drug classes affected. `tetX` confers tetracycline resistance, not carbapenem resistance. `AdeABC` has a broad substrate profile that includes tigecycline. The proposed experiment is nonsensical: clavulanate is a $\\beta$-lactamase inhibitor and has no interaction with tigecycline, the `tetX` enzyme, or the `AdeABC` pump. This test is completely irrelevant to the mechanisms in question.\n- **Verdict: Incorrect.**\n\nBased on the rigorous application of the provided first principles, option A is the only one that correctly predicts the phenotypes and proposes valid, mechanism-specific experimental tests.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "When faced with an infection caused by a pathogen armed with formidable resistance mechanisms, clinicians often resort to combination therapies. This hands-on calculation simulates a core task in the clinical microbiology lab: evaluating whether two drugs work better together. By calculating the Fractional Inhibitory Concentration Index (FICI) from minimal inhibitory concentration (MIC) data, you will learn how to quantitatively assess drug synergy, a vital strategy in the fight against multidrug-resistant organisms .",
            "id": "4654989",
            "problem": "A clinical isolate of multidrug-resistant Acinetobacter baumannii is evaluated by broth microdilution and checkerboard microdilution. The minimal inhibitory concentration (MIC) of meropenem alone is measured as $32\\,\\text{mg}\\,\\text{L}^{-1}$, and the MIC of sulbactam alone is $16\\,\\text{mg}\\,\\text{L}^{-1}$. In the checkerboard microdilution assay, visible growth inhibition is observed at the combination containing $4\\,\\text{mg}\\,\\text{L}^{-1}$ meropenem with $4\\,\\text{mg}\\,\\text{L}^{-1}$ sulbactam. Using the definitions of the fractional inhibitory concentration (FIC) for each drug and the fractional inhibitory concentration index (FICI) employed in checkerboard analysis, compute the FICI for this drug pair against this isolate. Then, classify the interaction as synergistic, additive, indifferent, or antagonistic using the following widely used interpretive cutoffs: synergy if $\\leq 0.5$, additivity if $> 0.5$ and $\\leq 1$, indifference if $> 1$ and $\\leq 4$, and antagonism if $> 4$. Round your final FICI to three significant figures. Report only the FICI as your final numeric answer (unitless).",
            "solution": "The problem statement is first subjected to a rigorous validation process.\n\n**Step 1: Extract Givens**\n-   Minimal Inhibitory Concentration (MIC) of meropenem alone, $\\text{MIC}_{\\text{MEM}}$: $32\\,\\text{mg}\\,\\text{L}^{-1}$\n-   Minimal Inhibitory Concentration (MIC) of sulbactam alone, $\\text{MIC}_{\\text{SUL}}$: $16\\,\\text{mg}\\,\\text{L}^{-1}$\n-   Concentration of meropenem in the inhibitory combination, $\\text{C}_{\\text{MEM}}$: $4\\,\\text{mg}\\,\\text{L}^{-1}$\n-   Concentration of sulbactam in the inhibitory combination, $\\text{C}_{\\text{SUL}}$: $4\\,\\text{mg}\\,\\text{L}^{-1}$\n-   Interpretive cutoffs for the Fractional Inhibitory Concentration Index (FICI):\n    -   Synergy: $\\text{FICI} \\leq 0.5$\n    -   Additivity: $0.5 < \\text{FICI} \\leq 1$\n    -   Indifference: $1 < \\text{FICI} \\leq 4$\n    -   Antagonism: $\\text{FICI} > 4$\n-   Required precision: The final FICI value must be rounded to three significant figures.\n\n**Step 2: Validate Using Extracted Givens**\n-   **Scientifically Grounded:** The problem is scientifically valid. It describes a standard *in vitro* method (checkerboard microdilution) used in clinical microbiology to quantify the interaction between two antimicrobial agents. The organism (*Acinetobacter baumannii*), the drugs (meropenem and sulbactam), the concept of MIC, and the calculation of FICI are all well-established in the field of infectious diseases and antimicrobial susceptibility testing. The given MIC values are realistic for a multidrug-resistant isolate.\n-   **Well-Posed:** The problem is well-posed. It provides all necessary data and definitions (either explicitly or by standard convention, i.e., the definitions of FIC and FICI) to compute a unique numerical answer.\n-   **Objective:** The problem is stated in objective, quantitative terms, free of ambiguity or subjective interpretation.\n-   **Completeness and Consistency:** The problem is self-contained and internally consistent. The data provided are sufficient for the required calculation.\n-   **Other Flaws:** The problem does not violate any other validation criteria. It is a standard, formalizable scientific calculation.\n\n**Step 3: Verdict and Action**\nThe problem is deemed **valid**. A solution will be provided.\n\nThe Fractional Inhibitory Concentration Index (FICI) is a quantitative measure of the interaction between two antimicrobial agents. It is calculated from the Fractional Inhibitory Concentrations (FICs) of each drug.\n\nThe FIC for a given drug (Drug X) is defined as the ratio of its MIC in combination with another drug to its MIC when tested alone.\n$$ \\text{FIC}_{\\text{X}} = \\frac{\\text{MIC of Drug X in combination}}{\\text{MIC of Drug X alone}} $$\nThe problem provides the MIC of each drug in the inhibitory combination, which we denote as $\\text{C}_{\\text{MEM}}$ and $\\text{C}_{\\text{SUL}}$.\n\nFor meropenem (MEM), the FIC is:\n$$ \\text{FIC}_{\\text{MEM}} = \\frac{\\text{C}_{\\text{MEM}}}{\\text{MIC}_{\\text{MEM}}} $$\nFor sulbactam (SUL), the FIC is:\n$$ \\text{FIC}_{\\text{SUL}} = \\frac{\\text{C}_{\\text{SUL}}}{\\text{MIC}_{\\text{SUL}}} $$\nThe FICI is the sum of the individual FICs:\n$$ \\text{FICI} = \\text{FIC}_{\\text{MEM}} + \\text{FIC}_{\\text{SUL}} $$\nNow, we substitute the given values into these equations.\n\nThe given values are:\n$\\text{MIC}_{\\text{MEM}} = 32\\,\\text{mg}\\,\\text{L}^{-1}$\n$\\text{MIC}_{\\text{SUL}} = 16\\,\\text{mg}\\,\\text{L}^{-1}$\n$\\text{C}_{\\text{MEM}} = 4\\,\\text{mg}\\,\\text{L}^{-1}$\n$\\text{C}_{\\text{SUL}} = 4\\,\\text{mg}\\,\\text{L}^{-1}$\n\nFirst, we calculate the FIC for meropenem:\n$$ \\text{FIC}_{\\text{MEM}} = \\frac{4\\,\\text{mg}\\,\\text{L}^{-1}}{32\\,\\text{mg}\\,\\text{L}^{-1}} = \\frac{4}{32} = \\frac{1}{8} = 0.125 $$\nNext, we calculate the FIC for sulbactam:\n$$ \\text{FIC}_{\\text{SUL}} = \\frac{4\\,\\text{mg}\\,\\text{L}^{-1}}{16\\,\\text{mg}\\,\\text{L}^{-1}} = \\frac{4}{16} = \\frac{1}{4} = 0.25 $$\nFinally, we sum the individual FICs to obtain the FICI:\n$$ \\text{FICI} = \\text{FIC}_{\\text{MEM}} + \\text{FIC}_{\\text{SUL}} = 0.125 + 0.25 = 0.375 $$\nThe problem requires the answer to be rounded to three significant figures. The calculated value $0.375$ already has three significant figures (the digits $3$, $7$, and $5$).\n\nBased on the provided interpretive criteria, since $\\text{FICI} = 0.375$ and $0.375 \\leq 0.5$, the interaction between meropenem and sulbactam against this isolate is classified as synergistic. However, the problem asks only for the numerical value of the FICI.",
            "answer": "$$\\boxed{0.375}$$"
        }
    ]
}